Induction of Effector and Memory Cellular Immunity in a Patient with Long-Term Complete Molecular Response to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Copyright © 2020 by S. Karger AG, Basel..
This case report is about a patient who suffered from Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia. The blasts were positive for myeloid-lineage markers including CD13 and CD33, as well as B-cell-lineage markers. Minor bcr-abl1 mRNA was detected by real-time quantitative polymerase chain reaction. Chromosomal abnormality monosomy 7 was also observed, in addition to Ph1. Despite treatment difficulties that were anticipated based on these findings, the patient had long-time complete molecular response (CMR) for approximately 5 years using chemotherapy and two tyrosine kinase inhibitors, imatinib and dasatinib. Lymphocytes were elevated after the patient switched from imatinib to dasatinib, and a T-cell receptor (TCR) V beta gene repertoire analysis revealed oligoclonal expansion of effector and memory cytotoxic T lymphocytes (CTLs), including Wilms tumor 1-specific CTLs. More specifically, the two memory CTLs expressing TCR V beta 3 and V beta 7.1 gradually increased after dasatinib administration. The activation and maintenance of anti-leukemia immunity may have allowed the patient to obtain long-time CMR. These results highlight that obtaining memory CTLs for leukemia cells may lead to safe withdrawal from dasatinib in the patient.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Case reports in oncology - 13(2020), 2 vom: 07. Mai, Seite 990-996 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jo, Tatsuro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bcr-abl1 |
|---|
| Anmerkungen: |
Date Revised 02.10.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1159/000508997 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315701595 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315701595 | ||
| 003 | DE-627 | ||
| 005 | 20231225155504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000508997 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315701595 | ||
| 035 | |a (NLM)32999661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jo, Tatsuro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Induction of Effector and Memory Cellular Immunity in a Patient with Long-Term Complete Molecular Response to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.10.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 by S. Karger AG, Basel. | ||
| 520 | |a This case report is about a patient who suffered from Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia. The blasts were positive for myeloid-lineage markers including CD13 and CD33, as well as B-cell-lineage markers. Minor bcr-abl1 mRNA was detected by real-time quantitative polymerase chain reaction. Chromosomal abnormality monosomy 7 was also observed, in addition to Ph1. Despite treatment difficulties that were anticipated based on these findings, the patient had long-time complete molecular response (CMR) for approximately 5 years using chemotherapy and two tyrosine kinase inhibitors, imatinib and dasatinib. Lymphocytes were elevated after the patient switched from imatinib to dasatinib, and a T-cell receptor (TCR) V beta gene repertoire analysis revealed oligoclonal expansion of effector and memory cytotoxic T lymphocytes (CTLs), including Wilms tumor 1-specific CTLs. More specifically, the two memory CTLs expressing TCR V beta 3 and V beta 7.1 gradually increased after dasatinib administration. The activation and maintenance of anti-leukemia immunity may have allowed the patient to obtain long-time CMR. These results highlight that obtaining memory CTLs for leukemia cells may lead to safe withdrawal from dasatinib in the patient | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Cytotoxic T lymphocyte | |
| 650 | 4 | |a Philadelphia chromosome | |
| 650 | 4 | |a Wilms tumor 1 | |
| 650 | 4 | |a bcr-abl1 | |
| 700 | 1 | |a Shioya, Haruna |e verfasserin |4 aut | |
| 700 | 1 | |a Tominaga, Hiroo |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Shizuka |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuzaka, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Yohei |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuo, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Taguchi, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Case reports in oncology |d 2008 |g 13(2020), 2 vom: 07. Mai, Seite 990-996 |w (DE-627)NLM195637992 |x 1662-6575 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:2 |g day:07 |g month:05 |g pages:990-996 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000508997 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 2 |b 07 |c 05 |h 990-996 | ||